|
|
Merck & Co. Climbed To Another New High For The Year
11/20/2009 4:52 PM ET
(RTTNews) -
Merck & Co. (MRK: News ) announced Friday morning that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of ELONVA, as a treatment in controlled ovarian stimulation in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology program.
Merck & Co. climbed during the first half hour of trade Friday and rose further around mid-afternoon. The stock finished up by 1.13 at $36.46. Merck has been gaining ground for the last 2 1/2 weeks and closed at its fifth consecutive new high for the year.
Click here to receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: contact editorial@rttnews.com
|
|
|
|
|
More After hours |
|
|
4 Articles
|
|
|
|
|
|
|
|
|